



Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat (Website: www.samratpharmachem.com)

Corp Office : 701/702 Business Square, M. A. Road, Andheri (West), Mumbai - 400 058 (CIN: L24230GJ1992PLC017820)

(Rs. in Lakhs)

Statement of Standalone Audited Results for the Quarter and for the Year Ended 31 MARCH, 2017

Particulars	Quarter Ended			Year Ended	
	31-Mar-17 (Unaudited)	31-Dec-16 (Unaudited)	31-Mar-16 (Unaudited)	31-Mar-17 (Audited)	31-Mar-16 (Audited)
1 (a). Net Income from Sales / Services	1,303.56	1,810.57	1,997.36	7,106.50	6,185.52
(b). Other Operating Income	0.27	0.21	3.02	7.91	7.69
Total Income	1,303.83	1,810.78	2,000.38	7,114.41	6,193.21
2. Expenditure					
a) Consumption of Raw Materials	1,050.81	1,368.92	1,621.80	6,074.57	5,065.47
b) Purchase of Traded Goods	70.86	143.74	172.27	214.60	580.12
c) (Increase)/Decrease in Stock in Trade & WIP	(66.22)	63.10	20.23	(49.50)	(31.42)
d) Employee Costs	39.13	27.26	31.53	112.13	97.78
e) Depreciation	34.57	12.18	11.23	69.48	44.34
f) Other Expenditure					
(i) Manufacturing Expenses	81.46	51.61	73.20	249.30	210.26
(ii) Administration Expenses	10.74	12.61	13.39	61.91	57.79
(iii) Selling & Distribution Expenses	12.54	22.63	25.94	71.67	85.70
g) Total	1,233.89	1,702.05	1,969.59	6,804.16	6,110.04
3. Profit from Operations before Other Income, Interest and Exceptional Items	69.94	108.73	30.79	310.25	83.17
4. Other Income	1.61	1.10	1.56	6.82	12.97
5. Profit before Interest and Exceptional items	71.55	109.83	32.35	317.07	96.14
6. Finance Expenses	10.57	15.74	10.42	67.73	50.86
7. Profit after Interest but before Exceptional items	60.98	94.09	21.93	249.34	45.28
8. Exceptional Items	0.00	0.00	(0.42)	0.00	(0.42)
9. Profit/(Loss) from ordinary activities before tax	60.98	94.09	21.51	249.34	44.86
10. Tax expense (incl deferred tax)	(36.07)	(29.07)	(3.91)	(92.78)	(14.74)
11. Net Profit/(Loss) from ordinary activities after tax	24.91	65.02	17.60	156.56	30.12
12. Extraordinary Items (Net of tax expense)	0.00	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period	24.91	65.02	17.60	156.56	30.12
14. Paid-up Equity Share Capital	308.97	308.97	308.97	308.97	308.97
15. Reserves excluding revaluation reserves				1,223.20	1,066.64
16. Earnings per share					
a) Basic and diluted EPS before extraordinary items for the period, year-to-date, previous year	0.81	2.10	0.57	5.07	0.97
b) Basic and diluted EPS after extraordinary items for the period, year-to-date, previous year	0.81	2.10	0.57	5.07	0.97
17. Public shareholding					
-- Number of shares	1,610,553	1,611,753	1,628,282	1,610,553	1,628,282
-- Percentage of shareholding	52.13	52.17	52.70	52.13	52.70
18. Promoters and promoter group shareholding**					
a) Pledged/ Encumbered					
-- Number of shares	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00
b) Non-encumbered					
-- Number of shares	1,479,147	1,477,947	1,461,418	1,479,147	1,461,418
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
-- Percentage of shares (as a % of the total share capital of the company)	47.87	47.83	47.30	47.87	47.30



Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Standalone Statement of Assets and Liabilities		
Particulars	As at 31-Mar-2017 (Audited)	As at 31-Mar-2016 (Audited)
<u>EQUITY AND LIABILITIES</u>		
SHAREHOLDERS' FUNDS:		
(a) Capital	308.97	308.97
(b) Reserves and Surplus	1,223.20	1,066.64
(c) Money Received Against Share Warrants	0.00	0.00
Sub total- Shareholders' Fund	1,532.17	1,375.61
SHARE APPLICATION MONEY PENDING ALLOTMENT	0.00	0.00
NON - CURRENT LIABILITIES		
(a) Long-Term Borrowings	116.73	153.22
(b) Deferred Tax Liabilities (Net)	30.36	42.30
(c) Other Long-Term Liabilities	19.63	0.00
(d) Long-Term Provisions	0.00	0.00
Sub total- Non Current Liabilities	166.72	195.52
CURRENT LIABILITIES		
(a) Short-Term Borrowings	542.09	370.31
(b) Trade Payables	740.83	1,608.53
(c) Other Current Liabilities	85.53	57.46
(d) Short-Term Provisions	58.49	10.04
Sub total- Current Liabilities	1,426.94	2,046.34
Total - Equity and Liabilities	3,125.83	3,617.47
<u>ASSETS</u>		
NON-CURRENT ASSETS		
(a) Fixed Assets	721.40	728.23
(b) Non-Current Investment	0.00	0.00
(c) Deferred Tax Assets (Net)	0.00	0.00
(d) Long-Term Loans And Advances	16.60	11.89
(e) Other Non-Current Assets	40.58	40.57
Sub total- Non Current Assets	778.58	780.69
CURRENT ASSETS		
(a) Current Investment	0.10	200.10
(b) Inventories	702.14	567.82
(c) Trade Receivables	1,184.22	1,610.47
(d) Cash And Cash Equivalents	245.80	349.60
(e) Short-term loans and advances	2.28	7.64
(f) Other current assets	212.71	101.15
Sub total- Current Assets	2,347.25	2,836.78
Total - Assets	3,125.83	3,617.47



Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Notes:

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The above results have been taken on record by the Board of Directors at its Meeting held on Tuesday, 30 May 2017 at the Corporate Office of the Company.
3. The above figures are after accounting for a net foreign exchange gain/(loss) of Rs.49.97 lakhs during the year.
4. The figures of the quarter ended 31 Mar 2017 and 31 Mar 2016 are the balancing figures between the audited figures in respect of full financial years and the published (unaudited) up to the third quarter of relevant financial year.
5. Information on investor complaints pursuant to clause 41 of the listing agreement for the quarter ended 31 March, 2017:

Opening Balance as on	1-Jan-2017	0
Received during the quarter		0
Disposed of during the quarter		0
Closing Balance as on	31-Mar-2017	0

6. The figures for the previous period have been regrouped where necessary to conform to current period's classification.

By order of the Board of Directors
For Samrat Pharmachem Limited

Rajesh Mehta
Executive Director

Place : Mumbai
Date : 30 May 2017